Citations

Mayo Clinic

Showing 10 of 108537 citations.

Severe acute liver disease in adults: Contemporary role of histopathology
Gouw, Annette S.H. , Brunt, Elizabeth M. , Callea, Francesco , Dienes, Hans‐Peter, Goodman, Zachary , Hübscher, Stefan G. , Kakar, Sanjay , Lackner, Carolin , Park, Young Nyun , Roberts, Eve A., Schirmacher, Peter , Terracciano, Luigi , Wanless, Ian R., Zen, Yoh , Brunt, Elizabeth M , Kleiner, David Erwin , Zen, Yoh , Burt, Alastair D , Park, Young Nyun , Clouston, Andrew Donald , Tiniakos, Dina , Bédossa, Pierre , Kakar, Sanjay , Torbenson, Michael

Histopathology | May 22, 2024 | Volume: 85 | Issue: 4 | Pages: 549-561

10.1111/his.15212 | PMID 38773813 Get It

Liver biopsies have consistently contributed to our understanding of the pathogenesis and aetiologies of acute liver disease. As other diagnostic modalities have been developed and refined, the role of biopsy in the management of patients with acute liver failure (ALF), acute‐on‐chronic liver failure (ACLF) and acute hepatitis, including acute liver injury (ALI), has changed. Liver biopsy remains particularly valuable when first‐line diagnostic algorithms fail to determine aetiology. Despite not being identified as a mandatory diagnostic tool in recent clinical guidelines for the management of ALF or ACLF, many centres continue to undertake biopsies given the relative safety of transjugular biopsy in this setting. Several studies have demonstrated that liver biopsy can provide prognostic information, particularly in the context of so‐called indeterminate hepatitis, and is extremely useful in excluding conditions such as metastatic tumours that would preclude transplantation. In addition, its widespread use of percutaneous biopsies in cases of less severe acute liver injury, for example in the establishment of a diagnosis of acute presentation of autoimmune hepatitis or confirmation of a probable or definite drug‐induced liver injury (DILI), has meant that many centres have seen a shift in the ratio of specimens they are receiving from patients with chronic to acute liver disease. Histopathologists therefore need to be equipped to deal with these challenging specimens. This overview provides an insight into the contemporary role of biopsies (as well as explant and autopsy material) in diagnosing acute liver disease. It outlines up‐to‐date clinical definitions of liver injury and considers recent recommendations for the diagnosis of AIH and drug‐induced, autoimmune‐like hepatitis (DI‐AIH).
CAD -Related Disorder (EIEE-50) in an Infant With Cortical Visual Impairment
Thurman, Sarah , Fischer, Callie R. , Gavrilova, Ralitza, Brodsky, Michael C., Fischer, Callie, Guerin, Julie, Brodsky, Michael, Thurman, Sarah Allen , Guérin, J.

Journal of Child Neurology | May 22, 2024 | Volume: 39 | Issue: 5-6 | Pages: 218-221

10.1177/08830738241255247 | PMID 38775036 Get It

Purpose To document the association of CAD-related disorder (EIEE-50) with cortical visual impairment. Observations An 8-month-old Caucasian boy with whole genome sequencing confirming 2 variants in the gene CAD, who presented with severe seizures, microcephaly, hyperreflexia, hypotonia, anemia, and severe cortical visual impairment. Magnetic resonance imaging (MRI) of the brain noted thickened cortical gray matter along the right calcarine fissure as well as changes suggesting malformation of cortical development. Empiric uridine monophosphate supplementation has significantly improved seizure activity, hypotonia, and development and has led to resolution of anemia. Conclusions and Importance CAD-related disorder is treatable and may affect visual cortical development causing severe secondary cortical visual impairment, a newly described clinical manifestation.
Neutrophil reduction attenuates the severity of lung injury in the early phase of pneumococcal pneumonia in mice
Taenaka, Hiroki , Fang, Xiaohui , Maishan, Mazharul , Trivedi, Alpa , Wick, Katherine D. , Gotts, Jeffrey E. , Calfee, Carolyn S. , Matthay, Michael A. , Calfee, Carolyn S , Matthay, Michael A , Martin, Thomas R.

American Journal of Physiology-Lung Cellular and Molecular Physiology | May 22, 2024 | Volume: 327 | Issue: 2 | Pages: L141-L149

10.1152/ajplung.00113.2024 | PMID 38772909 Get It

Neutrophil accumulation is a key feature of ARDS, but their contribution to the pathogenesis is still uncertain. We investigated the effect of reducing neutrophils in a clinically relevant mouse model of pneumococcal pneumonia treated with antibiotics. When appropriate antibiotics were administered, neutrophil reduction with Ly6G antibody markedly attenuated lung injury and improved oxygenation. In the early phase of bacterial pneumonia, neutrophils contribute to the severity of lung injury, although they also participate in host defense.
A Clinician’s Guide to the Implementation of Point-of-Care Ultrasound (POCUS) in the Outpatient Practice
Overgaard, Joshua , Thilagar, Bright P. , Bhuiyan, Mohammed Nadir , Thilagar, Bright , Bhuiyan, M Nadir

Journal of Primary Care & Community Health | May 22, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241255576 | PMID 38773821 Get It

Point-of-care ultrasound (POCUS) is a valuable clinical tool used at the patient bedside to rapidly assess a wide variety of symptoms and problems which would otherwise take hours or even days. Though it has become the standard of care in Emergency Medicine and is becoming so in hospital internal medicine, less uptake has been appreciated in the outpatient setting despite reported interest from clinicians practicing there. A number of common barriers have been cited to explain this gap in use, which usually include access to equipment, mentorship, and time. In this review we present a proposed framework for clinicians who have an interest in implementing POCUS in their outpatient practice which we hope can mitigate some of these barriers and provide a more streamlined pathway to their desired goals.
Global epidemiology of early‐onset upper gastrointestinal cancer: trend from the Global Burden of Disease Study 2019
Danpanichkul, Pojsakorn , Auttapracha, Thanida , Kongarin, Siwanart , Jaruvattanadilok, Supitchaya , Saowapa, Sakditad , Suparan, Kanokphong , Liangpunsakul, Suthat , Wallace, Michael B. , Lui, Rashid , Wijarnpreecha, Karn , Wallace, Michael B , Danpanichkul, Pojsakorn , Ponvilawan, Ben , Simadibrata, Daniel Martin , Duangsonk, Kwanjit , Wijarnpreecha, Karn

Journal of Gastroenterology and Hepatology | May 22, 2024 | Volume: 39 | Issue: 9 | Pages: 1856-1868

10.1111/jgh.16620 | PMID 38772743 Get It

AbstractBackground and AimIn recent years, there has been a growing incidence of gastrointestinal cancer in young individuals. Despite its significant morbidity and mortality, research on upper gastrointestinal (UGI) cancer in young populations has been relatively limited. Therefore, studies on the epidemiological changes of this cancer are needed.MethodsUsing data from the Global Burden of Disease Study 2019, we examined the incidence, death, and disability‐adjusted life years (DALYs) from UGI cancers in the young, namely, early‐onset esophageal cancer (EOEC) and early‐onset gastric cancer (EOGC). These results were stratified by sex, geographical region, country, and sociodemographic index.ResultsThere was a total of 185 140 cases, 120 289 deaths, and 5.70 million DALYs attributable to early‐onset UGI cancers globally. From 2010 to 2019, the global incidence, death, and DALYs rates of early‐onset UGI cancers decreased. In contrast, the incidence rates increased in both EOEC (+1.15%) and EOGC (+0.21%) in the Eastern Mediterranean region.ConclusionsOver the past decade, the burden of UGI cancer in the young has decreased. However, it has increased in the Eastern Mediterranean region. Further research to elucidate the attributable risk factors in this population is warranted.
Stem cells, cell therapies, and bioengineering in lung biology and diseases 2023
Hynds, Robert E. , Magin, Chelsea M. , Ikonomou, Laertis , Aschner, Yael , Beers, Michael F. , Burgess, Janette K. , Heise, Rebecca L. , Hume, Patrick S. , Krasnodembskaya, Anna , Mei, Shirley H. J. , Park, Jin‐Ah , Reynolds, Susan D. , Tschumperlin, Daniel J. , Tanneberger, Alicia E. , Waters, Christopher M. , Zettler, Patricia J. , Weiss, Daniel J. , Ryan, Amy L. , Krasnodembskaya, Anna D , Park, Jin-Ah , Tschumperlin, Daniel J , Waters, Christopher M , Ryan, Amy L , Burgess, Janette K , Misharin, Alexander V. , Vaidyanathan, Sriram

American Journal of Physiology-Lung Cellular and Molecular Physiology | May 21, 2024 | Volume: 327 | Issue: 3 | Pages: L327-L340

10.1152/ajplung.00052.2024 | PMID 38772903 Get It

Repair and regeneration of a diseased lung using stem cells or bioengineered tissues is an exciting therapeutic approach for a variety of lung diseases and critical illnesses. Over the past decade, increasing evidence from preclinical models suggests that mesenchymal stromal cells, which are not normally resident in the lung, can be used to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating the use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those involving stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in our understanding of the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise during lung development and participate in normal and pathological remodeling after lung injury. For the 2023 Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases Conference, scientific symposia were chosen to reflect the most cutting-edge advances in these fields. Sessions focused on the integration of “omics” technologies with function, the influence of immune cells on regeneration, and the role of the extracellular matrix in regeneration. The necessity for basic science studies to enhance fundamental understanding of lung regeneration and to design innovative translational studies was reinforced throughout the conference.
NTRK3 -Rearranged Prostatic Acinar Adenocarcinoma: Report of a Patient and Review of the Literature
Whaley, Rumeal D. , McCarthy, Michael, Zia, Hamid , Al‐Kateb, Hussam , Cheville, John C. , Gupta, Sounak , Al-Kateb, Hussam, Gupta, Sounak , Tekin, Burak , Pitel, Beth A.

International Journal of Surgical Pathology | May 21, 2024 | Volume: 33 | Issue: 1 | Pages: 204-208

10.1177/10668969241253197 | PMID 38772598 Get It

Molecular investigations have led to increased therapeutic options for prostatic adenocarcinoma. A single case report of a PRPSAP1 :: NTRK3 gene fusion occurring in prostate cancer was previously reported. A review of the literature revealed that NTRK gene rearrangements are exceedingly rare molecular events in prostate cancer. NTRK gene fusions can be oncogenic drivers or develop as resistance mechanisms. The tumor-agnostic approvals of TRK inhibitors by the FDA provide additional rationale for molecular investigations of aggressive prostatic adenocarcinomas. This may prove to be an additional therapeutic option for patients with aggressive prostatic carcinomas refractory to initial therapy. We report a case of an aggressive castrate-resistant prostatic adenocarcinoma with a BMP6 :: NTRK3 gene fusion.
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Kumar, Shaji , Rees, Matthew J. , D’Agostino, Mattia , Leypoldt, Lisa Beatrice , Weisel, Katja C , Gay, Francesca

American Society of Clinical Oncology Educational Book | May 21, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1200/edbk_433520 | PMID 38772002 Get It

Despite significant improvement in the outcomes of patients with newly diagnosed multiple myeloma (NDMM) with novel therapies, there is still an underserved high-risk (HR) population that experiences early disease progression and death. With the median survival crossing 10 years, we defined ultrahigh-risk (uHR)MM as MM leading to death within 24-36 months of diagnosis and HRMM as MM leading to death within 36-60 months. Several features have emerged as markers of uHRMM: the co-occurrence of two or more high-risk cytogenetic abnormalities, extramedullary disease, plasma cell leukemia and a high-risk gene expression profiling signature. The heterogeneous risk definition across trials, the few trials available designed for HR patients, and the small HR subgroups in all-comers trials make it difficult to generate recommendations with high levels of evidence. Nevertheless, regardless of treatment administered, several studies consistently showed that achieving and maintaining measurable residual disease negativity is now considered the main factor able to mitigate the adverse prognosis related to baseline features. For fit patients with HR transplant-eligible (TE) NDMM, quadruplet induction/consolidation treatment with anti-CD38 monoclonal antibodies, immunomodulatory agents, proteasome inhibitors and dexamethasone, and autologous stem-cell transplant and maintenance with, if available, at least a doublet combination could be considered the option of choice. For non-TE NDMM, considering the recent data generated and carefully reviewing those upcoming, quadruplet treatment consisting of anti-CD38 monoclonal antibodies, immunomodulatory agents, proteasome inhibitors, and dexamethasone should also be considered. Future trials integrating BCMA-directed novel generation immunotherapies hold great potential for further advancing the treatment landscape in all NDMM patients with HR disease.
Transformative Peer Connections: Early Experiences From the ASCO Palliative Care Community of Practice
Tsang, Mazie , Dhawan, Natasha , Patel, Rushil , Burbage, Darcy , Zhang, Tingting , Al‐Mondhiry, Jafar , Sedhom, Ramy , Tsang, Mazie , Bergerot, Cristiane Decat , McCollom, Joseph

American Society of Clinical Oncology Educational Book | May 21, 2024 | Volume: 44 | Issue: 3 | Pages: No page available

10.1200/edbk_100047 | PMID 38772001 Get It

The integration of palliative care into routine oncology practice is the standard of care by most leading cancer organizations. Palliative medicine helps to deliver higher quality of care at a lower cost. However, there are barriers to implementing palliative oncology at many institutions for myriad reasons. In this article, we discuss an innovative strategy that ASCO implemented called the Communities of Practice (CoP). We share our experiences as the Palliative Care CoP and how our group seeks to develop processes and structures to collectively promote systemic change and enhance palliative care delivery for people with cancer. Our Palliative Care CoP engages with senior leaders, administrators, and those in power to achieve a shared vision of delivering holistic health care for people with serious illness. We continue to evolve to meet our members' growing needs by addressing eight main domains: (1) increasing palliative care education and resources; (2) creating opportunities for global palliative care research; (3) providing peer mentorship and community building; (4) engaging with patient advocates; (5) supporting and developing interdisciplinary teams; (6) assisting with professional development and identity formation, especially for trainees and early career faculty; (7) extending our outreach through social media; and (8) enhancing the clinical practice of palliative oncology. The ASCO CoP has been a vital forum to realize ASCO's mission of conquering cancer and advancing the Art and Science of Cancer Care: From Comfort to Cure.
Outcomes of Visceral Arterial Interposition Graft Reconstruction for Locally Advanced Pancreatic Cancer
Colglazier, Jill J. , Kendrick, Michael L. , Kalra, Manju, DeMartino, Randall, Bower, Thomas C., Truty, Mark J. , Mendes, Bernardo C. , Demartino, Randall D, Yonkus, Jennifer A. , Alva‐Ruiz, Roberto , Kalra, Manju , Rasmussen, Todd E. , DeMartino, Randall R.

Annals of Surgery | May 21, 2024 | Volume: 281 | Issue: 6 | Pages: 1006-1014

10.1097/sla.0000000000006350 | PMID 38771952 Get It

Objective: The aim of this study is to determine perioperative outcomes and the patency of interposition conduits for visceral arterial reconstruction in this setting. Background: Visceral arterial encasement in locally advanced pancreatic cancer was historically a contraindication for surgery. With modern, effective neoadjuvant strategies, our recent experience has made advanced vascular resection and reconstruction feasible in selected patients. Methods: A retrospective review was performed of patients undergoing pancreatic tumor resection with en bloc arterial resection and interposition revascularization between June 2002 and October 2022. Endpoints included graft patency, vascular-related complications, reinterventions, morbidity, and mortality. Results: Visceral arterial reconstruction with interposition grafting was performed in 111 patients undergoing en bloc arterial resections for pancreatic cancer. Graft types included autologous arterial conduits (n=66, 58 superficial femoral arteries (SFA) and 8 splenic arteries), cryopreserved arterial allografts (n=24), autologous saphenous veins (n=12), synthetic conduits (n=8), and composite autologous artery and synthetic (n=1). Perioperative 90-day mortality decreased significantly over time to 5% in the last 6 years. Vascular complications related to arterial reconstruction occurred in 11% (n=12) and included pseudoaneurysm (n=6), graft thrombus (n=2), stenosis requiring reintervention (n=2), hepatic failure (n=1), and hepatic and intestinal ischemia (n=1). Nine (8%) patients underwent vascular-related reinterventions. After a median follow-up of 17 months, primary patency was 81% for the entire cohort and was highest in the SFA group (95%). The donor limb/harvest site complication rate was 8% with 100% primary patency. Conclusion: Visceral arterial resection with interposition reconstruction for locally advanced pancreatic cancer can be performed with acceptable vascular morbidity and durable patency. Autologous SFA was the most suitable conduit for reconstructions in our experience, with the highest primary patency.